Core Viewpoint - The company reported a revenue of 120 million yuan for the first half of 2025, reflecting a year-on-year growth of 6.01%, but continued to incur a net loss of 105 million yuan, although this was an improvement compared to a loss of 113 million yuan in the same period last year [1]. Financial Performance - Revenue for the first half of 2025 reached 120 million yuan, marking a 6.01% increase year-on-year [1]. - The net profit attributable to shareholders was -105 million yuan, an improvement from -113 million yuan in the previous year [1]. - Basic earnings per share were -0.163 yuan [1]. Business Operations - The company's cell and gene therapy CDMO business faced challenges due to macroeconomic changes, industry conditions, and downstream demand [1]. - The execution order prices for the CDMO business remained at a low level [1]. - The operational costs, including depreciation, energy consumption, and administrative expenses, were relatively high, contributing to the overall loss [1]. - The gross profit margin for the cell and gene therapy CDMO business remained negative [1].

Financial Performance - The overall performance has improved compared to the same period last year, although the company remains in a loss position[4] - The company reported a significant increase in revenue, reaching $X million, representing a Y% growth compared to the previous quarter[15] - The company achieved operating revenue of CNY 119.85 million in the first half of the year, representing a year-on-year increase of 6.01%[25] - The total profit for the period was a loss of CNY 102.77 million, an improvement compared to a loss of CNY 113.36 million in the same period last year[25] - The net profit attributable to shareholders was a loss of CNY 104.57 million, which is a reduction in loss by CNY 8.78 million compared to the previous year[25] - The company achieved a revenue of CNY 119.85 million, representing a year-on-year growth of 6.01%[134] - The revenue from the cell and gene therapy CRO business was CNY 40.70 million, up 3.79% year-on-year[134] - The revenue from the cell and gene therapy CDMO business was CNY 65.62 million, remaining stable compared to the previous year[134] - The net loss attributable to the parent company was CNY 104.57 million, a decrease in loss of CNY 8.78 million compared to the previous year[134] Operational Challenges - The company's cell and gene therapy CDMO business continues to be affected by macroeconomic changes and downstream demand, resulting in a negative gross margin[4] - The company is experiencing high operational costs, including depreciation, energy costs, and administrative expenses[4] - The company is in the process of ramping up production capacity at its Lingang industrial base, which requires time[4] - The company’s CDMO business has seen a decline in gross profit margins, attributed to market pricing pressures and increased operational costs[128] - The company faces risks related to inventory impairment, with a total inventory value of CNY 77.52 million, accounting for 3.66% of total assets[130] - The company is exposed to industry risks due to the dependence on the cell and gene therapy sector, which is subject to rapid technological changes and regulatory uncertainties[131] Research and Development - The company is focusing on enhancing R&D efficiency and expanding into new business areas to improve competitiveness and market penetration[5] - The company is investing G million in R&D for new technologies, aiming to enhance product offerings and improve operational efficiency[15] - Research and development expenses accounted for 19.37% of operating revenue, down 6.35 percentage points from the previous year[24] - The total R&D investment for the period was approximately ¥23.21 million, a decrease of 20.18% compared to ¥29.08 million in the same period last year, with R&D investment accounting for 19.37% of operating revenue[114] - The company has filed 2 invention patents and 8 utility model patents during the reporting period, bringing the total to 27 invention patents and 16 utility model patents[112] Market Position and Strategy - The cell and gene therapy sector is identified as a key development direction in the biopharmaceutical industry, supported by national and local policies[5] - The company aims to provide a "one-stop" service from laboratory research to commercial production for a more diverse customer base[5] - The company is expanding its market presence in region D, aiming for a market share increase of E% by the end of the fiscal year[15] - Recent acquisitions have strengthened the company's portfolio, adding F new products and enhancing its competitive edge in the market[15] - The company is focused on addressing technical bottlenecks in the production of cell and gene therapy products to improve safety, efficacy, and accessibility[38] - The company is actively participating in the commercialization of innovative therapies, with a focus on expanding into new therapeutic areas such as cardiovascular and autoimmune diseases[39] Future Outlook - The company provided an optimistic outlook for the next quarter, projecting revenue growth of B% and an increase in user engagement metrics[15] - Future guidance indicates a commitment to sustainable practices, with plans to reduce operational carbon footprint by J% over the next five years[15] - The company has initiated a strategic partnership with entity I, expected to drive synergies and enhance market reach[15] Regulatory and Compliance - The report includes forward-looking statements that are subject to various uncertainties and risks[7] - The company has no plans for profit distribution or capital reserve conversion for the half-year period[163] - The company is included in the list of publicly disclosed environmental information companies, with one subsidiary reporting environmental information[167] - The series of guidelines issued by the government aims to standardize drug development, ensuring long-term healthy industry growth and promoting high-level demand for CRO/CDMO services[52] Financial Management - The company has completed a stock repurchase plan, acquiring 18,726,690 shares for a total amount of 99.94 million yuan, representing 2.8853% of the total share capital[85] - The company’s cash flow from operating activities improved, with a net outflow of CNY 88.50 million, an increase compared to the previous year[138] - Cash and cash equivalents at the end of the period amounted to ¥287,005,381.69, representing 13.54% of total assets, a decrease of 34.69% compared to the previous year[142] - Short-term borrowings increased by 192.23% to ¥204,713,214.99, accounting for 9.66% of total assets, due to new bank loans and repurchase financing[142] Technological Advancements - The company is leveraging advancements in gene editing and delivery technologies, including AI integration, to enhance the development of cell and gene therapies[36] - The company has developed a high-yield cell adaptation process based on HEK293 cells, achieving over 100% increase in lentivirus production compared to conventional cell lines[104] - The company has optimized its production processes for various viral vectors, achieving a 50% increase in yield for AAV production cell lines compared to commercial cell lines[105] - The company has established a comprehensive AAV serotype screening service platform, covering the entire process from library construction to high-throughput sequencing[101] Human Resources - The number of R&D personnel decreased to 105 from 145 year-on-year, with the proportion of R&D staff in total employees dropping to 15.49%[122] - The total compensation for R&D personnel was 17.24 million RMB, down from 21.92 million RMB in the previous year[122]

Core Viewpoint - The company reported a slight increase in revenue for the first half of 2025, but continued to face significant net losses [2] Financial Performance - The company's revenue for the first half of 2025 was approximately 120 million, representing a year-on-year increase of 6.01% [2] - The net loss attributable to shareholders for the same period was approximately 105 million [2] - Basic earnings per share for the first half of 2025 were a loss of 0.163 [2] - In comparison, the revenue for the same period in 2024 was approximately 113 million, with a net loss of about 113 million and a basic earnings per share loss of 0.175 [2]

证券代码：688238 证券简称：和元生物 公告编号：2025-058 和元生物技术（上海）股份有限公司 关于召开 2025 年半年度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 投资者可于 2025 年 8 月 20 日(星期三)至 8 月 26 日(星期二)16:00 前登录上 证 路 演 中 心 网 站 首 页 点 击 " 提 问 预 征 集 " 栏 目 或 通 过 公 司 邮 箱 zhengquanbu@obiosh.com 进行提问。公司将在说明会上对投资者普遍关注的问 题进行回答。 和元生物技术（上海）股份有限公司（以下简称"公司"）已于 2025 年 8 月 19 日披露公司《2025 年半年度报告》，为便于广大投资者更全面深入地了解 公司 2025 年半年度经营成果、财务状况，公司计划于 2025 年 8 月 27 日(星期三) 下午 15:00-16:00 举行 2025 年半年度业绩说明会，就投资者关心的问题进行交 流。 一、说明会类型 本次业绩说明会以网络互动形式召 ...

为践行以"投资者为本"的上市公司发展理念，维护公司全体股东利益，增 强投资者信心，促进公司健康可持续发展，和元生物技术（上海）股份有限公司 （以下简称"公司"）基于对公司未来发展前景的信心及内在价值的认可，结合 自身发展战略和经营情况，于 2025 年 5 月制定了公司 2025 年度"提质增效重回 报"专项行动方案（以下简称"行动方案"）。2025 年上半年，公司根据行动方 案内容积极开展和落实相关工作，现将 2025 年上半年行动方案的主要执行进展 情况报告如下： 一、聚焦主营业务，提升核心竞争力 2025 年上半年，国内生物医药领域机遇与挑战交织并存，呈现出多元化发 展与市场激烈竞争的复杂态势，公司坚守"客户第一""守正创新"的核心经营 理念，聚焦细胞和基因治疗 CRO/CDMO 主营业务，以乐观稳健的姿态应对外部变 化。各事业部锚定年初经营目标和提质增效重点方向，持续高效推进客户资源储 备和品牌影响力，积极推行各项行动方案，不断练好内功，提升运营管理能力， 为业务的长远发展筑牢根基。 报告期内，公司实现营业收入 11,985.50 万元，较上年同期增幅 6.01%；实 现归属于母公司所有者的净利润-1 ...

和元生物技术（上海）股份有限公司 第四届董事会独立董事专门会议第一次会议资料 和元生物技术（上海）股份有限公司 第四届董事会独立董事专门会议第一次会议决议 会议时间：2025 年 8 月 15 日上午 9:00-9:15 会议地点：上海市临港新片区沧海路 3888 号 召集人：独立董事高国垒先生 主持人：独立董事高国垒先生 经审议，独立董事认为：公司 2025 年半年度募集资金存放、管理与实际使 用情况，符合《上市公司募集资金监管规则》《上海证券交易所科创板上市公司 自律监管指引第 1 号——规范运作》等相关规定，公司对募集资金采用了专户存 储，专款专用，并及时履行了相关信息披露义务，募集资金的存放、管理与使用 情况同公司募集资金相关信息披露的内容一致，不存在违规使用募集资金的行为， 不存在损害公司和全体股东特别是中小股东利益的情况。 2、议案表决结果： 和元生物技术（上海）股份有限公司 第四届董事会独立董事专门会议第一次会议资料 同意票数 4 票，反对票数 0 票，弃权票数 0 票，回避票数 0 票。 和元生物技术（上海）股份有限公司（以下简称"公司"）第四届董事会独 立董事专门会议第一次会议于 2025 ...

证券代码：688238 证券简称：和元生物 公告编号：2025-057 和元生物技术（上海）股份有限公司 关于 2025 年半年度募集资金存放、管理与实际使用 情况的专项报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 根据中国证券监督管理委员会（以下简称"中国证监会"）发布的《上市公 司募集资金监管规则》（以下简称"《监管规则》"）和上海证券交易所发布的《上 海证券交易所科创板上市公司自律监管指引第 1 号——规范运作》（以下简称 "《规范运作》"）等有关规定，和元生物技术（上海）股份有限公司（以下简称 "公司"）董事会编制了《2025 年半年度募集资金存放、管理与实际使用情况的 的专项报告》，具体如下： 一、募集资金基本情况 (一)实际募集资金的金额及到账情况 根据中国证监会于 2022 年 1 月 11 日出具的《关于同意和元生物技术（上海） 股份有限公司首次公开发行股票注册的批复》（证监许可〔2022〕61 号），并经 上海证券交易所同意，公司向社会公开发行人民币普通股（A 股）100,000,000 股，每股 ...

和元生物公告，2025年上半年营业收入1.2亿元，同比增长6.01%。归属于上市公司股东的净亏损1.05亿 元，上年同期净亏损1.13亿元。 ...

Summary of Key Points Core Viewpoint - The 2024 A-share Secretary Data Report indicates that the total salary of A-share listed company secretaries reached 4.086 billion yuan, with an average annual salary of 754,300 yuan, highlighting the significant role of secretaries in connecting investors and listed companies [1][2]. Group 1: Overall Salary and Demographics - The total salary for A-share listed company secretaries in 2024 is 4.086 billion yuan, with an average annual salary of 754,300 yuan [1]. - Among the secretaries, those aged 40 and below constitute 43% of the market, while those aged 50 and above account for 22% [1]. - The educational background of secretaries shows that 34% hold a bachelor's degree, 52% have a master's degree, and 14% possess a doctoral degree [1]. Group 2: Industry-Specific Salary Insights - The average annual salary for secretaries in the pharmaceutical and medical service sector is 839,200 yuan [2]. - The distribution of salaries shows that 24% earn below 500,000 yuan, 48% earn between 500,000 and 1 million yuan, and 28% earn above 1 million yuan [2]. - The top three highest-paid secretaries are Gilbert Shing Chung Li from Kanglong Chemical with 1.9855 million yuan, Gao Dapeng from Zhaoyan New Drug with 1.7384 million yuan, and Xu Xiangke from Kailaiying with 1.6114 million yuan [2].

Core Insights - The report highlights that in 2024, the total salary of A-share listed company secretaries reached 4.086 billion yuan, with an average annual salary of 754,300 yuan [1] - A total of 1,144 company secretaries earned over 1 million yuan, accounting for more than 21% of the total [1] Salary Distribution - The average annual salary for company secretaries in the medical and healthcare services sector is 839,200 yuan [2] - The distribution of salaries shows that 24% earn below 500,000 yuan, 48% earn between 500,000 and 1 million yuan, and 28% earn above 1 million yuan [2] - The top three highest-paid company secretaries are Gilbert Shing Chung Li from Kanglong Chemical with 1.9855 million yuan, Gao Dapeng from Zhaoyan New Drug with 1.7384 million yuan, and Xu Xiangke from Kailaiying with 1.6114 million yuan [2] Age and Education Distribution - Company secretaries aged 40 and below constitute 43% of the market, while those aged 50 and above account for 22% [1] - The educational background of company secretaries shows that 34% hold a bachelor's degree, 52% have a master's degree, and 14% possess a doctoral degree [1] - Among the doctoral degree holders, there are 7 individuals, with the only full-time doctoral company secretary in the industry being Cao Nai'en from Huaxia Eye Hospital [1]